Drug Profile
ARN 2966
Alternative Names: 2-PMAP; AGN-PC-0031SD; ARN2966Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator New York University School of Medicine
- Developer Aria Neurosciences; New York University School of Medicine
- Class Pyridines; Small molecules
- Mechanism of Action Amyloid beta-protein precursor inhibitors; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (IV)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 16 Jul 2017 Preclinical trials in Alzheimer's disease in USA (IV) before July 2017